Table 3. Maximum % LINE-1 demethylation... | American Society of Hematology

Table 3.

Maximum %LINE-1 demethylation by treatment cycle

Phase 2 overall stage cycle	Patients, n	Treatment	Mean baseline*	Maximum %LINE-1 demethylation change from baseline		Difference (oral–IV) in mean maximum %LINE-1 demethylation
Phase 2 overall stage cycle	Patients, n	Treatment	Mean baseline*	LSM	95% CI	Estimate	95% CI†
1	40	Oral C/D	79.349	10.726	9.161-12.291	−1.079	−3.320 to 1.163
	38	IV decitabine	79.119	11.805	10.200-13.410
2	31	Oral C/D	77.626	9.340	7.387-11.292	−0.017	−2.736 to 2.701
	33	IV decitabine	77.298	9.357	7.465-11.249

Phase 2 overall stage cycle	Patients, n	Treatment	Mean baseline*	Maximum %LINE-1 demethylation change from baseline		Difference (oral–IV) in mean maximum %LINE-1 demethylation
Phase 2 overall stage cycle	Patients, n	Treatment	Mean baseline*	LSM	95% CI	Estimate	95% CI†
1	40	Oral C/D	79.349	10.726	9.161-12.291	−1.079	−3.320 to 1.163
	38	IV decitabine	79.119	11.805	10.200-13.410
2	31	Oral C/D	77.626	9.340	7.387-11.292	−0.017	−2.736 to 2.701
	33	IV decitabine	77.298	9.357	7.465-11.249

C/D, cedazuridine/decitabine.

Baseline for cycle 1 was last available value on or before day 1 of cycle 1; baseline for cycle 2 was value on day 1 of cycle 2.

Generated using ANOVA model separately for cycles 1 and 2.